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The susceptibility of HIV-1 to chemokine-mediated inhibition may be lost as a consequence of the expanded usage of
chemokine co-receptors frequently occurring in clade B isolates obtained from individuals with advanced disease. Since
chemokine-based immune intervention is under intense investigation, it is crucial to determine its potential effect on primary
dualtropic HIV isolates characterized by simultaneous utilization of CCR5 and CXCR4 chemokine co-receptors (R5X4 viruses).
In the present study, the CCR5 binding chemokine regulated upon activation normal T cell expressed and secreted (RANTES)
strongly inhibited the replication of two of eight primary R5X4 viruses in mitogen-activated primary peripheral blood
mononuclear cells (PBMC). The CXCR4 antagonist AMD3100 efficiently suppressed the replication of other two HIV isolates,
whereas the remaining four viruses were partially inhibited by treatment with either RANTES or AMD3100. The potency of
chemokine-mediated inhibition was influenced by PBMC donor variability, but it was usually independent from the levels of
expression of CCR5 or CXCR4. Dual co-receptor usage was maintained by the viruses after two serial passages on U87.CD4
astrocytic cell lines expressing exclusively either CCR5 or CXCR4. The gp120 env variable domains were sequenced before
and after passages on U87.CD4 cells. Virus replication into U87.CD4-CXCR4 cells did not result in changes in the V3 region
but perturbed the dominant env V4 sequence. Interestingly, double passage onto U87.CD4-CXCR4 cells determined the loss
of susceptibility to RANTES inhibition. In conclusion, interference with CCR5 may efficiently inhibit the replication of at least
some dualtropic HIV-1 strains, whereas forced CXCR4 usage may result in viral escape from CCR5-dependent inhibitory
effects. © 2001 Academic Press
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CC-chemokines, and particularly regulated upon acti-
vation normal T cell expressed and secreted (RANTES),
protect cells from infection with macrophage-tropic non-
syncytium inducing (NSI) HIV-1 strains using CCR5 (R5
viruses) as entry co-receptor (Alkhatib et al., 1996; Berger
et al., 1998; Choe et al., 1996; Cocchi et al., 1995; Deng et
al., 1996). Conversely, the CXC-chemokine stromal-cell-
derived factor-1 (SDF-1a), the unique ligand of CXCR4
Bleul et al., 1996), inhibits entry and replication of T-
ropic SI (X4) viruses, but not of R5 HIV-1 strains (Feng et
l., 1996; Oberlin et al., 1996). However, RANTES has
een also reported to enhance replication of X4 mono-
ropic and dualtropic R5X4 viruses (Dolei et al., 1998;
ordon et al., 1999; Kinter et al., 1998; Trkola et al., 1999).
hese findings suggested the possibility that RANTES
nd other CCR5 binding chemokines could force HIV-1 to
volve into more virulent forms in vivo by inducing a
henotypic switch from CCR5 to CXCR4 usage as a
esult of both inhibition of R5 virus entry and enhance-
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253ent of X4 HIV replication (Michael and Moore, 1999;
osier et al., 1999). In support of this hypothesis, loss of
ensitivity to RANTES-mediated inhibitory effects on vi-
us replication has been documented in sequential iso-
ates obtained from infected individuals, extending their
o-receptor usage from CCR5 to CXCR4 along with dis-
ase progression (Bjorndal et al., 1997; Scarlatti et al.,
997).
Aim of our study was to investigate the susceptibility to
hemokine-mediated inhibitory effects of R5X4 dual-
ropic primary isolates with respect to treatment with
ither RANTES or AMD3100, a selective CXCR4 antago-
ist (Schols et al., 1997). Different donors’ PBMC, levels
f chemokine co-receptor expression, and variations in
heir gp120 env sequences before and after forced rep-
ication in either CCR5- or CXCR4-expressing cells were
tudied.
RESULTS
ANTES and AMD3100 inhibit the replication of
rimary R5X4 dualtropic isolates
Eight viruses were selected by both CCR5 and CXCR4
sage (R5X4) according to their fusogenic and replicative
apacities in U87.CD4 cell lines. One hundred microliters
0042-6822/01 $35.00
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254 GHEZZI ET AL.of undiluted primary HIV-1 isolates was adsorbed to PHA
blasts (106 cells/ml) of different HIV seronegative individ-
als. RANTES or AMD3100 was then added on indepen-
ent wells and supplemented a second time 72 h after
nfection. RANTES (100 ng/ml) suppressed the replica-
ion of two (SR-2 and SR-9) of eight R5X4 HIV strains (Fig.
FIG. 1. Patterns of interference with primary dualtropic virus replica-
tion by RANTES and AMD3100. RANTES efficiently inhibited the repli-
cation of SR-2 and SR-9, whereas AMD3100 suppressed SR-4 and SR-6
virus spreading in human PHA blasts (top). The remainder viruses
showed intermediate susceptibility to either agent (bottom). Results are
expressed as means 6 SE of RT activities of culture quadruplicates
and triplicates for untreated cultures and for treated cultures, respec-
tively, 7 days p.i. in a single experiment.
FIG. 2. Influence of PBMC donor-to-donor variability on RANTES a
inhibition of peak of RT activities (occurring between 7 and 12 days p.i.
The whiskers indicate the range of the data with the boxes extending from the
values. Statistical analysis was carried out according to the Kruskal–Wallis c). No increased levels of suppression were observed
ith 1000 ng/ml of the chemokine, whereas its inhibitory
ffect was lost between 10 and 1 ng/ml with all the tested
iruses (data not shown). Therefore, the range of RAN-
ES concentration that inhibited the R5X4 replication in
HA blasts was similar to that required for inhibition of
5 monotropic viruses (Cocchi et al., 1995; Dragic et al.,
996; Jansson et al., 1996). SR-4 and SR-6 R5X4 primary
solates were insensitive to RANTES inhibitory effects,
hereas the CXCR4 antagonist AMD3100 (1 mg/ml) sup-
pressed their replication in PHA blasts. Four additional
primary isolates (SR-3, SR-5, SR-7, and SR-8) were par-
tially inhibited by treatment with either RANTES or
AMD3100 (Fig. 1).
To demonstrate whether RANTES inhibitory effect on
dualtropic HIVs was dependent upon inhibition of viral
entry, the region spanning from R to U5 within the 59 LTR
(R-U5) was amplified. RANTES prevented proviral DNA
synthesis of both R5 and R5X4 HIVs, at 24 and 48 h p.i.
consistently with interference of viral entry (data not
shown).
Donor variability and cell-surface expression of HIV
co-receptors as determinants of R5X4 virus
susceptibility to RANTES or AMD3100
To characterize the broad range of inhibitory effects
observed with RANTES and AMD3100, three primary
isolates (SR-2, SR-3, and SR-4) were selected as proto-
types of the observed patterns. The potency of RANTES
inhibitory effects on R5X4 virus replication varied sub-
stantially among PHA blasts of independent donors,
ranging from complete suppression in the case of SR-2
(median inhibition: 72%) to poor inhibition for SR-3 and
SR-4 (median inhibitions: 32.5 and 19%, respectively) (Fig.
2). Conversely, AMD3100 (1 mg/ml), tested in parallel
ultures, efficiently inhibited SR-4 replication (median
D3100 inhibitory effects on dualtropic HIV isolates. The percentage
er RANTES (left) or AMD3100 (right) over untreated cultures is shown.nd AM
) by eith25th to the 75th percentile, whereas the horizontal lines are the median
omputed with the Dunn’s multiple comparison test.
i
f
s
R
e
a
s
p
s
9
i
t
a
i
o
T
o
i
C
v
U
S
i
t
t
l
T
c
e
d
w
t sing e
a is.
255R5X4 HIV ISOLATES, PBMC, RANTES, CXCR4 ANTAGONIST, ENVinhibition of 96.5%), whereas SR-2 and SR-3 replication
was partially suppressed by this agent (median inhibi-
tions: 61 and 65.5%, respectively, Fig. 2).
To verify whether RANTES and AMD3100 suppression
of dualtropic virus replication was correlated to prefer-
ential expression of CCR5 or CXCR4 co-receptors, flow
cytometric analyses of PBMC were carried out in freshly
isolated PBMC and PHA blasts from seven additional
donors. Mitogenic stimulation induced up-regulation of
both CCR5 and CXCR4 on CD41 T cells with median fold
nduction compared to unstimulated cells of 6- and 10-
old, respectively (not shown). As shown in Fig. 3, a
tronger inhibition of SR-2 and SR-3 virus replication by
ANTES was observed when the donors’ PHA blasts
xpressed the highest levels of CCR5 and the lowest
mounts of CXCR4, although this correlation was not
tatistically significant. Conversely, AMD3100 sup-
ressed almost completely the replication of SR-4 in
even of seven PBMC donors (median suppression:
4%), whereas it blocked SR-2 and SR-3 replication only
n part (with median inhibitions of 54 and 77%, respec-
FIG. 3. Correlation analyses between RANTES or AMD3100 percent
hose of untreated cultures) vs percentage of CD41 PHA blasts expres
nd the statistics were calculated by the Spearman correlation analysively) in a donor-dependent fashion (Fig. 3). Interestingly,
negative correlation was found between the potency of inhibition of SR-4 replication by AMD3100 and the levels
f CCR5 expression (Spearman’s r 5 20.89, P 5 0.01).
herefore, the levels of chemokine receptor expression
n the cell surface may influence in part the susceptibil-
ty to different primary isolates to co-receptor inhibitors.
o-receptor usage and characterization of gp120 Env
ariable regions before and after passage onto
87.CD4 cells
To test whether the relative susceptibility of SR-2,
R-3, and SR-4 primary isolates to RANTES or AMD3100
nhibition was dependent upon the dominance of mono-
ropic R5 or X4 viral variants present in their swarms,
hese viruses were passaged twice on U87.CD4 cell
ines expressing either CCR5 or CXCR4 co-receptors.
he viruses resulting from the second passage on these
ell lines were analyzed for co-receptor usage. Of inter-
st, all the three second-passage viruses maintained
ual co-receptor usage regardless of which co-receptor
as utilized for spreading in U87.CD4 cells (Fig. 4).
ibition of virus replication (calculated at the peaks of RT activity over
ither CXCR4 or CCR5. Seven independent PBMC donors were tested,age inhThe gp120 Env variable regions play a major role in the
nteraction with both CD4 and chemokine receptor (Riz-
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256 GHEZZI ET AL.zuto et al., 1998) and can influence the viral cellular
ropism for macrophages or T lymphocytes, CCR5 vs
XCR4 co-receptor usage and the sensitivity of HIV iso-
ates to RANTES inhibition (Bleul et al., 1996; Cho et al.,
1998; Cocchi et al., 1996; Jansson et al., 1996; Shioda et
l., 1991; Smyth et al., 1998). The hypervariable V1/V2, V3,
nd V4/V5 region of gp120 Env of the three HIV isolates
ere amplified by PCR after extraction of the virion-
ssociated genomic RNA and sequenced before and
fter two serial passages on U87.CD4 cells expressing
ither CCR5 or CXCR4. Figure 5 shows the amino acid
aa) alignments of V1/V2, V3, and V4/V5 variable regions
f gp120 Env. The serial passages on U87.CD4 express-
ng CCR5 determined a number of changes including aa
nsertions in V1/V2 regions of SR-2 and SR-3 primary
solates, whereas SR4 was essentially unaffected (Fig.
). Valine (V) at position 45 changed into methionine (M)
n V2 during the passages of SR-3 on U87.CD4 express-
ng CCR5. This mutation has been described as a cor-
elate of loss of MIP-1a inhibitory effects on R5 viruses
dapted to replicate in the presence of the chemokine
Maeda et al., 2000). Furthermore, a deletion at the same
osition was found in SR-2 (Fig. 5). However, these
hanges were not associated with loss of sensitivity to
ANTES-mediated inhibition, as shown in Fig. 6.
To investigate whether mutation or selection of mi-
or variants occurred during these in vitro passages,
he V3 region of the three dual-tropic isolates was
FIG. 4. Forced co-receptor usage and dualtropism. Serial passages
of SR-2, SR-3, and SR-4 primary HIV-1 isolates on U87.CD4 expressing
either CCR5 or CXCR4. The range of peak RT activities were scored as
follows: 1111 5 $5000 cpm/ml; 111 5 2000 2 5000 cpm/ml; 11
1000 2 2000 cpm/ml; 1 5 #1000 cpm/ml.mplified by PCR, and 10 clones per each isolate were
enerated and sequenced. SR-3 V3 sequences werehe most heterogeneous as compared to other viral
solates, whereas a predominant species was present
n 7 of 10 clones of SR-2 with 3 clones containing a few
ariations as compared to the predominant species.
R-4 was the most homogenous virus, in that only one
inor variant was detected (Fig. 5). Of interest, the
ercent similarity to ADA of the env V3 predominant
pecies of the dual-tropic viruses ranged from 74
SR-4) to 87% (SR-3), whereas the percent homology
ith the X4 prototype NL4-3 V3 env region showed
alues from 50 (SR-2) to 58% (SR-3; data not shown).
hus, our dual-tropic HIV isolates appeared more re-
ated to a macrophage-tropic rather than to a TCLA
irus in their env V3 sequence. The sum of positive
nd negative charges of env V3 was also evaluated. In
his regard, charges ranging from 12 to 15 are typical
f macrophage-tropic strains, whereas values greater
han 17 characterize T-tropic viruses (Ugolini et al.,
999). The overall range of the net charges of env V3
f our primary isolates was from 14 to 18, whereas
none of the single variants reached the values char-
acteristic of X4 viruses such as NL4-3 and MN. Single
aa positions have been associated to viral tropism. For
example, a change at position 11 from a neutral to a
positively charged aa has been associated to both the
NSI to SI phenotypic switch (De Jong et al., 1992;
Fouchier et al., 1992) and to the extension of corecep-
tor usage from CCR5 to CXCR4 (Connor et al., 1997;
Scarlatti et al., 1997). As expected, SR-2 and SR-4
isolates had an arginine (R) in the predominant variant
in this position (Fig. 5). However, the less-frequent
viral variants cloned from the primary isolates were
characterized by neutral aa such as serine (S) or
glycine (G). Unexpectedly, SR-3 showed a neutral S at
position 11 in all clones despite its SI phenotype and
R5X4 usage; its V3 net charge, however, was esti-
mated 18, and therefore it can be considered more
similar to X4 than R5 viruses (Fig. 5). Moreover, iso-
leucine (I) at position 30, conferring CCR5 usage, was
found in 100% of clones obtained from dual-tropic
viruses, as previously shown (Chan et al., 1999; Hung
et al., 1999). After two serial passages on U87.CD4
cells expressing either CCR5 or CXCR4, the I residue
at position 30 was maintained. The I at position 27,
also involved in the CCR5 usage (Hung et al., 1999),
was present in SR-3 isolate, whereas it was present
only in 2 of 10 clones of SR-2, but it was selected after
passage on U87.CD4 expressing CCR5 (Fig. 5). A se-
lection of minor quasispecies present in the original
isolate occurred for SR2 and SR3 after R5/R5 pas-
sages, whereas emergence of a mutant in V3 was
noted for SR4.
The aa alignments of the V4/V5 variable regions of
gp120 Env are also shown in Fig. 5. The serial passages
on U87.CD4 expressing CXCR4 did not change the se-
quence of the predominant species with the notable
freque
dicate
257R5X4 HIV ISOLATES, PBMC, RANTES, CXCR4 ANTAGONIST, ENVexception of the V4 region of SR-2 strain. In addition to
several aa changes, insertion of 5 aa in addition to
several other aa changes within V4 occurred in SR-
2X4/X4 (Fig. 5).
FIG. 5. Amino acid (aa) sequence alignment of the variable regions
isolates before and after two serial passages on U87.CD4-CCR5 (R
independent clones per each primary isolate are reported. The observed
are indicated on the right. Dots denote aa identity, whereas dashes in
FIG. 6. Loss of susceptibility to RANTES-mediated inhibition in du-
altropic viruses passaged twice on U87.CD4-CXCR4 cells. RANTES-
mediated inhibition of SR-2 and SR-3 infection in PHA-blasts before (I°
Isolate) and after two passages on either U87.CD4-CCR5 (R5/R5) or
U87.CD4-CXCR4 (X4/X4). The percentage inhibition of peak of RT ac-
tivities (12 days p.i.) by RANTES over untreated cultures is shown.Dissociation of co-receptor usage from RANTES
inhibitory effect on R5X4 HIV-1 isolates
SR-2 and SR-3 primary isolates changed their V1/V2
sequences after passages on U87.CD4 expressing
CCR5, and SR-2 changed its V4 after passage on
U87.CD4-CXCR4 cells. However, the replication of SR-2
and SR-3 virions after two serial passages onto U87.CD4-
CCR5 cells was still inhibited by RANTES. In sharp con-
trast, both SR-2 and SR-3 viruses completely lost their
sensitivity to RANTES inhibition after two serial pas-
sages on U87.CD4-CXCR4 (Fig. 6). These results indicate
that the env V3 region is not the only determinant of
RANTES inhibition of dualtropic viruses, whereas the
sequence variation in V4 could be responsible of the loss
of RANTES inhibitory effects on SR-2 replication. How-
ever, the Env structural requirement for entry of SR-3
might be different since no variations were detected in
20 Env, including V1/V2, V3, and V4/V5 of SR-2, SR-3, and SR-4 viral
or U87.CD4-CXCR4 cells (X4/X4). The V3 sequences from 10 to 13
ncy of each sequence is reported at the left, whereas their net charges
gaps to optimize the alignments.of gp1
5/R5)all SR-3 gp120 Env variable regions as compared to the
original primary isolate.
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258 GHEZZI ET AL.DISCUSSION
In the present study, we investigated the susceptibility
f a pool of randomly selected primary R5X4 dualtropic
IV-1 isolates to inhibition by chemokine receptor li-
ands of their replicative ability in PHA blasts of different
eronegative donors. Four of eight viral isolates were
trongly inhibited either by RANTES (2/4) or AMD3100
2/4), binding to CCR5 and CXCR4, respectively, whereas
he remaining four isolates showed partial susceptibility
o either co-receptor inhibitors. Donor variability and lev-
ls of cell-surface expression of CCR5 and CXCR4 influ-
nced the degree of inhibitory effects observed, how-
ver, without substantial changes of the observed pat-
erns. Although sequence variability was observed in the
p120 Env V3 variable loops of three prototypic primary
solates, their double passage onto U87.CD4 cells ex-
ressing exclusively CCR5 or CXCR4 did not sort out
onotropic viral variants in terms of co-receptor usage.
owever, forced use of CXCR4 resulted in the loss of
usceptibility to RANTES inhibitory effects in previously
ensitive HIV isolates. Molecular analysis suggests that
4 rather than V3 domain of gp120 Env may be an
mportant determinant of sensitivity and escape from
hemokine-mediated control of virus replication.
It is well documented that clade B HIV acquires mul-
iple chemokine receptors usage during disease pro-
ression (Connor et al., 1997; Scarlatti et al., 1997). Ex-
tension to CXCR4 utilization in addition to CCR5 has
been reported to coincide with the loss of chemokine-
mediated inhibition of viral replication (Jansson et al.,
1996). With the caveat that only a small number of pri-
mary isolates were investigated, our findings suggest
that single agonists or antagonists of CCR5 or CXCR4
can efficiently inhibit dualtropic viruses. Amino-terminal
modifications to RANTES have been shown to increase
its potency as inhibitor of HIV replication (Mosier et al.,
1999; Simmons et al., 1997). However, these compounds
ere not tested in the present study. No clear-cut corre-
ation was observed between the levels of CCR5 or
XCR4 expression on the PHA blast cell surface and the
otency of RANTES inhibition of SR-2 and SR-3. On the
ther hand, the potency of AMD3100 inhibition of SR-4
as significantly correlated to lower CCR5 expression,
uggesting that CXCR4 could be preferentially used by
R-4. In this regard, co-receptor competition for associ-
tion with CD4 has been recently shown to affect HIV
ntry and inhibition by chemokine receptors agonists
nd antagonists (Lee et al., 2000).
The dualtropic nature of the gp120 Env of the HIV-1
solates was not resolved into R5 and X4 monotropic
ariants by sequential passage in cell lines expressing
xclusively either CCR5 or CXCR4. However, two pas-
ages in CXCR4 expressing cell lines determined theoss of their susceptibility to the inhibitory effect of RAN-
ES of both SR-2 and SR-3 viruses. In this regard, it haseen suggested that CC-chemokines may enhance the
eplication of SI HIV-1 strains in CD41 T lymphocytes
Dolei et al., 1998; Gordon et al., 1999; Kinter et al., 1998;
rkola et al., 1999). However, these enhancing effects of
ANTES have been observed either at low m.o.i. (Kinter
t al., 1998) or after incubation of CD41 cells with high
1–10 mg/ml) concentrations of RANTES 48 h prior to
nfection (Gordon et al., 1999), conditions that were not
nvestigated in our study. However, the observed loss of
usceptibility to RANTES inhibitory effect after passage
n U87.CD4.CXCR4 cells suggests that forced utilization
f this chemokine receptor may profoundly alter the
esponsiveness to CCR5 binding chemokines as ob-
erved here with RANTES, at least in terms of inhibition
f HIV infection.
Recently, RANTES has been shown to suppress the
eplication of the chimeric 89.6-SF162 R5X4 virus ex vivo
n human lymphoid tissue (Glushakova et al., 1999), sug-
esting that some dualtropic viruses may be more sim-
lar to R5 in terms of viral spreading and chemokine
ensitivity than others (Glushakova et al., 1999). In the
resent study, although primary isolates containing sev-
ral quasispecies were used, dualtropic SR-2 and SR-3
IV isolates were more related to NSI rather than to SI
iruses in regard of homology to the gp120 env V3 se-
quence of the ADA and NL4-3 prototype HIV. Also the net
charge, and critical aa positions such as I at position 27
and 30 were more similar to NSI than SI laboratory-
adapted strains (Chan et al., 1999; Hung et al., 1999).
Conversely, our SR-4 primary HIV was poorly inhibited by
RANTES but efficiently blocked by AMD3100 particularly
in those PHA blasts that expressed the lowest CCR5
levels on their cell surface. Sequencing of the gp120 env
V3 before and after passages did not result in significant
changes within the V3 region. In addition, V1/V2 region(s)
confirmed that changes did occur during in vitro pas-
sages of SR-2 and SR-3 on U87.CD4 expressing CCR5. In
contrast, the gp120 Env V4 region of SR-2 changed sub-
stantially after two serial passages on U87.CD4 cells
expressing CXCR4, whereas infection on U87.CD4 ex-
pressing CCR5 cells did not alter the predominant spe-
cies of the primary viral isolate. These observations
indicate that sequences outside V3 through V4 can dis-
able RANTES inhibitory effects, supporting previous ob-
servations indicating that co-receptor utilization and tro-
pism of dualtropic viruses are determined by complex
interactions among multiple Env domains (Cho et al.,
1998; Smyth et al., 1998).
The mechanism underlying the profound inhibition of
some dualtropic HIVs by single chemokines or chemo-
kine antagonists, a phenomenon already noted and dis-
cussed by others (He et al., 1997), remains speculative.
Heterologous interactions among different chemokine
receptors such as CCR5, CXCR4, and CCR2b (at least in
its allelic variant V64I) leading to inhibition of co-recep-
tor-dependent HIV entry have been recently reported
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259R5X4 HIV ISOLATES, PBMC, RANTES, CXCR4 ANTAGONIST, ENV(Mellado et al., 1999). Therefore, CCR5 occupancy by
RANTES may not only prevent usage of this co-receptor
by the virus, but also influence in trans the ability of Env
to interact with CXCR4. The observation that a CXCR4
inhibitor such as AMD3100, devoid of signaling capacity,
exerted similar effects on our viruses than those ob-
served with RANTES does not support this interpretation.
On the other hand, the recent observation that pertussis
toxin and its B-oligomer subunit exert direct inhibitory
effects on R5 HIV entry and replication (Alfano et al.,
1999, 2000) challenges the “dogma” that chemokine-me-
diated inhibition of HIV infection does not require signal
transduction.
Finally, the demonstration that infection and replica-
tion of at least some dualtropic viruses are inhibited by
RANTES or AMD3100 fully supports the concept that
inhibitors of chemokine receptors are a promising new
class of antiviral agents potentially capable of preventing
infection in highly exposed individuals or limiting HIV
spreading in infected individuals.
MATERIALS AND METHODS
Viruses and cells
Primary HIV isolates from individuals with progressing
HIV-1 disease were generated by co-cultivation of 4 3
106 peripheral blood mononuclear cells (PBMC) with a
ixture of 3 3 106 allogeneic phytohemagglutinin
(PHA-P, Sigma Chemical Corp., St. Louis, MO)-stimulated
PBMC (PHA blasts) from two uninfected individuals in 10
ml of complete RPMI 1640 medium (Bio Whittaker, Ver-
viers, Belgium) containing 10% FCS (Sigma) and 20 U/ml
of recombinant interleukin-2 (IL-2) (Boehringer, Mann-
heim, Germany). At the peak of virus replication, moni-
tored in the culture supernatants by a standard Mg21-
dependent reverse transcriptase (RT) assay (Vicenzi et
al., 1994), supernatants were pooled, aliquoted, and
stored at 280°C. Infectious titers were determined by
the Reed-Muench formula (Koup et al., 1993) after infec-
tion of PHA blasts by serial dilutions of the viral stocks in
sextuplicates .4 weeks of infection. The viral phenotype
(i.e., syncytium-inducing, SI, or non-SI, NSI) was deter-
mined by infection of MT-2 cells (Koot et al., 1992). In
addition, 105 U87 astrocytic cells stably expressing either
D4 or CD4 plus CCR2b, CCR3, CCR5, or CXCR4 (Hill et
l., 1997) were infected with 100 ml of undiluted primary
isolates in 1 ml of DMEM plus 15% FCS.
One hundred microliters of undiluted primary HIV-1
isolates was adsorbed to PHA blasts (106 cells/ml) of
ifferent HIV seronegative individuals in a total volume of
ml for 1 h at 37°C; 5% CO2 cells were then diluted with
9 ml of complete medium and seeded in 48-well plastic
plates (1 ml/well) (Falcon, Becton Dickinson Labware,
Lincoln Park, NJ). RANTES (R&D Systems Inc., Minneap-
olis, MN), or AMD3100 was then added on independentwells, and supplemented a second time 72 h after infec-
tion.
Proviral DNA quantification
Primers M667 (59-GGCTAACTAGGGAACCCACTG-39)
and AA55 (59-CTGCTAGAGATTTTCCACACTGAC-39), fol-
lowed by hybridization to the labeled oligonucleotide
probe CG24 (59-CTCAATAAAGCTTGCCTTGAGTGC-39)
were used to amplify a portion of gag according to
published procedures (Zack et al., 1990).
FACS analysis
PHA blasts were stained with PE-conjugated anti-CD4
mAb and FITC-conjugated anti-CXCR4 (clone 12G5, R&D
Systems), anti-CCR5 (clone 45531.11, R&D Systems)
mAbs, or FITC/PE-conjugated isotype-matched control
mAbs. Stained cells were then analyzed by flow cytom-
etry (FACScan, Becton Dickinson).
PCR and sequencing
Virion RNA was extracted from 40 ml of supernatant by
the guanidinium thiocyanate method (Menzo et al., 1998)
and retrotranscribed by poly d(N)6. The following primers
ere used for amplification of the V1-V2 regions: sense
59-GATATAATCAGTTTATGGGATC-39) and antisense (59-
CACAATAATGTATGGGAATTGG-39). For the V3 region,
he following primers were used: sense V31 (59-TCAG-
ACAGTACAATGTACACATGGAAT-39) antisense V32 (59-
GTAGAAAAATTCCCCTCCACAATTAAA-39) (Menzo et
l., 1998). Two microliters of the PCR reaction were
dded to a cloning kit ligation reaction (The Ligator, R&D
ystems, Abingdon, UK), and bacterial clones were
aised according to the manufacture’s instructions.
or the V4-V5 domains, the sense primer was V45f (59-
CTCAGGAGGGGACCCAGAAATTG-39) and antisense
rimer was V45r (59-ATAGTGCTTCCTGCTGCTCCCAA-
AA-39). Amplification reactions were carried out for 40
CR cycles. Sequencing was performed by fluores-
ence-labeled dNTPs in an automated sequencer (Mod-
l 373A, Perkin Elmer Cetus, Norwalk, CT). The se-
uences have been deposited with GenBank under Ac-
ession Nos. AF333189–AF333232.
ACKNOWLEDGMENTS
This work was entirely supported by grants of the Second National
Project of Research Against AIDS of the Istituto Superiore di Sanita`’
(ISS), Rome, Italy. S.G. is a recipient of a fellowship from the ISS, Rome,
Italy. Dr. Bahige Baroudy, (Schering-Plough, Res. Ins., Kenilworth, NJ)
kindly provided AMD3100.
REFERENCES
Alfano, M., Pushkarsky, T., Poli, G., and Bukrinsky, M. (2000). The
B-oligomer of pertussis toxin inhibits HIV-1 replication at multiple
stages. J. Virol. 74, 8767–8770.
Alfano, M., Schmidtmayerova, H., Amella, C. A., Pushkarsky, T., and
A260 GHEZZI ET AL.Bukrinsky, M. (1999). The B-oligomer of pertussis toxin deactivates
CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains.
J. Exp. Med. 190, 597–605.
lkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E.,
Murphy, P. M., and Berger, E. A. (1996). CC CKR5: A RANTES, MIP-
1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-
tropic HIV-1. Science 272, 1955–1958.
Berger, E. A., Doms, R. W., Fenyo, E. M., Korber, B. T., Littman, D. R.,
Moore, J. P., Sattentau, Q. J., Schuitemaker, H., Sodroski, J., and
Weiss, R. A. (1998). A new classification for HIV-1. Nature 391, 240.
Bjorndal, A., Deng, H., Jansson, M., Fiore, J. R., Colognesi, C., Karlsson,
A., Albert, J., Scarlatti, G., Littman, D. R., and Fenyo, E. M. (1997).
Coreceptor usage of primary human immunodeficiency virus type 1
isolates varies according to biological phenotype. J. Virol. 71, 7478–
7487.
Bleul, C. C., Farzan, M., Choe, H., Parolin, C., Clark-Lewis, I., Sodroski,
J., and Springer, T. A. (1996). The lymphocyte chemoattractant SDF-1
is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382,
829–833.
Chan, S. Y., Speck, R. F., Power, C., Gaffen, S. L., Chesebro, B., and
Goldsmith, M. A. (1999). V3 recombinants indicate a central role for
CCR5 as a coreceptor in tissue infection by human immunodefi-
ciency virus type 1. J. Virol. 73, 2350–2358.
Cho, M. W., Lee, M. K., Carney, M. C., Berson, J. F., Doms, R. W., and
Martin, M. A. (1998). Identification of determinants on a dualtropic
human immunodeficiency virus type 1 envelope glycoprotein that
confer usage of CXCR4. J. Virol. 72, 2509–2515.
Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P. D., Wu,
L., Mackay, C. R., LaRosa, G., Newman, W., Gerard, N., Gerard, C.,
and Sodroski, J. (1996). The beta-chemokine receptors CCR3 and
CCR5 facilitate infection by primary HIV-1 isolates. Cell 85, 1135–
1148.
Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C., and
Lusso, P. (1995). Identification of RANTES, MIP-1 alpha, and MIP-1
beta as the major HIV-suppressive factors produced by CD81 T
cells. Science 270, 1811–1815.
Cocchi, F., DeVico, A. L., Garzino-Demo, A., Cara, A., Gallo, R. C., and
Lusso, P. (1996). The V3 domain of the HIV-1 gp120 envelope glyco-
protein is critical for chemokine-mediated blockade of infection. Nat.
Med. 2, 1244–1247.
Connor, R. I., Sheridan, K. E., Ceradini, D., Choe, S., and Landau, N. R.
(1997). Change in coreceptor use correlates with disease progres-
sion in HIV-1-infected individuals. J. Exp. Med. 185, 621–628.
De Jong, J. J., De Ronde, A., Keulen, W., Tersmette, M., and Goudsmit, J.
(1992). Minimal requirements for the human immunodeficiency virus
type 1 V3 domain to support the syncytium-inducing phenotype:
Analysis by single amino acid substitution. J. Virol. 66, 6777–6780.
Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Di
Marzio, P., Marmon, S., Sutton, R. E., Hill, C. M., Davis, C. B., Peiper,
S. C., Schall, T. J., Littman, D. R., and Landau, N. R. (1996). Identifi-
cation of a major co-receptor for primary isolates of HIV-1. Nature
381, 661–666.
Dolei, A., Biolchini, A., Serra, C., Curreli, S., Gomes, E., and Dianzani, F.
(1998). Increased replication of T-cell-tropic HIV strains and CXC-
chemokine receptor-4 induction in T cells treated with macrophage
inflammatory protein (MIP)-1alpha, MIP-1beta and RANTES beta-
chemokines. AIDS 12, 183–190.
Dragic, T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Nagashima,
K. A., Cayanan, C., Maddon, P. J., Koup, R. A., Moore, J. P., and Paxton,
W. A. (1996). HIV-1 entry into CD41 cells is mediated by the chemo-
kine receptor CC-CKR-5. Nature 381, 667–673.
Feng, Y., Broder, C. C., Kennedy, P. E., and Berger, E. A. (1996). HIV-1
entry cofactor: Functional cDNA cloning of a seven-transmembrane,
G protein-coupled receptor. Science 272, 872–877.
Fouchier, R. A., Groenink, M., Kootstra, N. A., Tersmette, M., Huisman,
H. G., Miedema, F., and Schuitemaker, H. (1992). Phenotype-associ-
ated sequence variation in the third variable domain of the humanimmunodeficiency virus type 1 gp120 molecule. J. Virol. 66, 3183–
3187.
Glushakova, S., Yi, Y., Grivel, J. C., Singh, A., Schols, D., De Clercq, E.,
Collman, R. G., and Margolis, L. (1999). Preferential coreceptor utili-
zation and cytopathicity by dual-tropic HIV-1 in human lymphoid
tissue ex vivo. J. Clin. Invest. 104, R7–R11.
Gordon, C. J., Muesing, M. A., Proudfoot, A. E., Power, C. A., Moore, J. P.,
and Trkola, A. (1999). Enhancement of human immunodeficiency
virus type 1 infection by the CC-chemokine RANTES is independent
of the mechanism of virus-cell fusion. J. Virol. 73, 684–694.
He, J., Chen, Y., Farzan, M., Choe, H., Ohagen, A., Gartner, S., Busciglio,
J., Yang, X., Hofmann, W., Newman, W., Mackay, C. R., Sodroski, J., and
Gabuzda, D. (1997). CCR3 and CCR5 are co-receptors for HIV-1
infection of microglia. Nature 385, 645–649.
Hill, C. M., Deng, H., Unutmaz, D., Kewalramani, V. N., Bastiani, L.,
Gorny, M. K., Zolla-Pazner, S., and Littman, D. R. (1997). Envelope
glycoproteins from human immunodeficiency virus types 1 and 2 and
simian immunodeficiency virus can use human CCR5 as a corecep-
tor for viral entry and make direct CD4-dependent interactions with
this chemokine receptor. J. Virol. 71, 6296–6304.
Hung, C. S., Vander Heyden, N., and Ratner, L. (1999). Analysis of the
critical domain in the V3 loop of human immunodeficiency virus type
1 gp120 involved in CCR5 utilization. J. Virol. 73, 8216–8226.
Jansson, M., Popovic, M., Karlsson, A., Cocchi, F., Rossi, P., Albert, J.,
and Wigzell, H. (1996). Sensitivity to inhibition by beta-chemokines
correlates with biological phenotypes of primary HIV-1 isolates. Proc.
Natl. Acad. Sci. USA 93, 15382–15387.
Kinter, A., Catanzaro, A., Monaco, J., Ruiz, M., Justement, J., Moir, S.,
Arthos, J., Oliva, A., Ehler, L., Mizell, S., Jackson, R., Ostrowski, M.,
Hoxie, J., Offord, R., and Fauci, A. S. (1998). CC-chemokines enhance
the replication of T-tropic strains of HIV-1 in CD4(1) T cells: Role of
signal transduction. Proc. Natl. Acad. Sci. USA 95, 11880–11885.
Koot, M., Vos, A. H., Keet, R. P., de Goede, R. E., Dercksen, M. W.,
Terpstra, F. G., Coutinho, R. A., Miedema, F., and Tersmette, M. (1992).
HIV-1 biological phenotype in long-term infected individuals evalu-
ated with an MT-2 cocultivation assay. AIDS 6, 49–54.
Koup, R. A., Ho, D. D., Poli, G., and Fauci, A. S. (1993). Isolation and
quantitation of HIV in peripheral blood. Curr. Prot. Immunol. 12.2.1–
12.1.11.
Lee, S., Lapham, C. K., Chen, H., King, L., Manischewitz, J., Romantseva,
T., Mostowski, H., Stantchev, T. S., Broder, C. C., and Golding, H.
(2000). Coreceptor competition for association with CD4 may change
the susceptibility of human cells to infection with T-tropic and mac-
rophagetropic isolates of human immunodeficiency virus type 1.
J. Virol. 74, 5016–5023.
Maeda, Y., Foda, M., Matsushita, S., and Harada, S. (2000). Involvement
of both the V2 and V3 regions of the CCR5-tropic human immuno-
deficiency virus type 1 envelope in reduced sensitivity to macro-
phage inflammatory protein 1alpha. J. Virol. 74, 1787–1793.
Mellado, M., Rodriguez-Frade, J. M., Vila-Coro, A. J., de Ana, A. M., and
Martinez, A. C. (1999). Chemokine control of HIV-1 infection. Nature
400, 723–724.
Menzo, S., Sampaolesi, R., Vicenzi, E., Santagostino, E., Liuzzi, G.,
Chirianni, A., Piazza, M., Cohen, O. J., Bagnarelli, P., and Clementi, M.
(1998). Rare mutations in a domain crucial for V3-loop structure
prevail in replicating HIV from long-term non-progressors. AIDS 12,
985–997.
Michael, N. L., and Moore, J. P. (1999). HIV-1 entry inhibitors: Evading
the issue. Nat. Med. 5, 740–742.
Mosier, D. E., Picchio, G. R., Gulizia, R. J., Sabbe, R., Poignard, P., Picard,
L., Offord, R. E., Thompson, D. A., and Wilken, J. (1999). Highly potent
RANTES analogues either prevent CCR5-using human immunodefi-
ciency virus type 1 infection in vivo or rapidly select for CXCR4-using
variants. J. Virol. 73, 3544–3550.
Oberlin, E., Amara, A., Bachelerie, F., Bessia, C., Virelizier, J. L.,
Arenzana-Seisdedos, F., Schwartz, O., Heard, J. M., Clark-Lewis, I.,
Legler, D. F., Loetscher, M., Baggiolini, M., and Moser, B. (1996). The
261R5X4 HIV ISOLATES, PBMC, RANTES, CXCR4 ANTAGONIST, ENVCXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents
infection by T-cell-line-adapted HIV-1. Nature 382, 833–835.
Rizzuto, C. D., Wyatt, R., Hernandez-Ramos, N., Sun, Y., Kwong, P. D.,
Hendrickson, W. A., and Sodroski, J. (1998). A conserved HIV gp120
glycoprotein structure involved in chemokine receptor binding. Sci-
ence 280, 1949–1953.
Scarlatti, G., Tresoldi, E., Bjorndal, A., Fredriksson, R., Colognesi, C.,
Deng, H. K., Malnati, M. S., Plebani, A., Siccardi, A. G., Littman, D. R.,
Fenyo, E. M., and Lusso, P. (1997). In vivo evolution of HIV-1 co-
receptor usage and sensitivity to chemokine-mediated suppression.
Nat. Med. 3, 1259–1265.
Schols, D., Struyf, S., Van Damme, J., Este, J. A., Henson, G., and De
Clercq, E. (1997). Inhibition of T-tropic HIV strains by selective an-
tagonization of the chemokine receptor CXCR4. J. Exp. Med. 186,
1383–1388.
Shioda, T., Levy, J. A., and Cheng-Mayer, C. (1991). Macrophage and T
cell-line tropisms of HIV-1 are determined by specific regions of the
envelope gp120 gene. Nature 349, 167–169.Simmons, G., Clapham, P. R., Picard, L., Offord, R. E., Rosenkilde, M. M.,
Schwartz, T. W., Buser, R., Wells, T. N. C., and Proudfoot, A. E. (1997).Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes
by a novel CCR5 antagonist. Science 276, 276–279.
Smyth, R. J., Yi, Y., Singh, A., and Collman, R. G. (1998). Determinants of
entry cofactor utilization and tropism in a dualtropic human immu-
nodeficiency virus type 1 primary isolate. J. Virol. 72, 4478–4484.
Trkola, A., Gordon, C., Matthews, J., Maxwell, E., Ketas, T., Czaplewski,
L., Proudfoot, A. E., and Moore, J. P. (1999). The CC-chemokine
RANTES increases the attachment of human immunodeficiency virus
type 1 to target cells via glycosaminoglycans and also activates a
single transduction pathway that enhances viral infectivity. J. Virol.
73, 6370–6379.
Ugolini, S., Mondor, I., and Sattentau, Q. J. (1999). HIV-1 attachment:
Another look. Trends Microbiol. 7, 144–149.
Vicenzi, E., Dimitrov, D. S., Engleman, A., Migone, T. S., Purcell, D. F. J.,
Leonard, J., Englund, G., and Martin, M. A. (1994). An integration
defective U5 deletion mutant of HIV-1 reverts by eliminating addi-
tional LTR sequences. J. Virol. 68, 7879–7890.
Zack, J. A., Arrigo, S. J., Weitsman, S. R., Go, A. S., Haislip, A., and Chen,
I. S. (1990). HIV-1 entry into quiescent primary lymphocytes: Molec-
ular analysis reveals a labile, latent viral structure. Cell 61, 213–222.
